Treatment News : PrEP May Be Safe for Women Seeking to Get Pregnant

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 21, 2014

PrEP May Be Safe for Women Seeking to Get Pregnant

Research suggests Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis may be safe for the pregnancies of HIV-negative women when taken until just after conception, although a definite answer on the matter is still out of reach. Publishing their findings in JAMA, investigators in the Partners PrEP Study researched 1,785 mixed-HIV status heterosexual couples in which the woman was HIV negative, randomizing the women to receive daily oral tenofovir (598 women), daily Truvada (566 women) or a placebo (621 women).

The study began in June 2008. After PrEP proved effective at reducing the risk of HIV acquisition in 2011, the placebo group was discontinued. The participants were tested monthly for pregnancy, and they discontinued PrEP if they became pregnant.

There were 431 pregnancies during the trial. The pregnancy incidence per 100 person-years for the three respective groups was 10 in the placebo group, 11.9 in the tenofovir group and 8.8 for those who received Truvada. Before the placebo group was terminated, the rate of pregnancy loss among the groups was 42.5 percent in the Truvada group, 32.3 percent in the placebo group and 27.7 percent for those who just took tenofovir. After the discontinuation of the placebo group, the rate of pregnancy loss was 37.5 percent for the Truvada group and 36.7 percent for those taking just tenofovir. However, none of these differences in pregnancy incidence or loss were statistically significant, meaning they could have occurred by chance. Nor was there any statistically significant difference in birth outcomes or infant growth.

The authors of the paper caution that because PrEP was discontinued when the pregnancies were detected, and because the statistical analysis for the difference in birth outcomes resulted in wide estimate ranges, the door is open for actual differences between the three groups; as a result, this study cannot make any “definitive statements about the safety of PrEP in the periconception period.” (Periconception is the period before and shortly after conception.)

To read the JAMA article, click here.

Search: PrEP, pre-exposure prophylaxis, Truvada, tenofovir, emtricitabine, preganancy, JAMA, Partners PrEP.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.